Clinical Scorecard: Assessment of Pathological Breast Tumor Dimensions in Cases of Architectural Distortion: A Comparative Analysis of DM, DBT, US, CEM, and MRI

At a Glance

Key Highlights

• AD accounts for approximately 6% of abnormalities detected on screening mammography and can be caused by benign or malignant lesions.
• Pathological tumor size (pT-stage) is the gold standard for tumor staging, but clinical tumor size (cT-stage) assessed by imaging guides preoperative treatment decisions.
• This study compares the accuracy of DM, DBT, US, MRI, and CEM in measuring invasive carcinoma size in AD cases and evaluates the impact of including thin mammographic spicules in measurements.

Guideline-Based Recommendations

Diagnosis

• Use imaging techniques (DM, DBT, US, MRI, CEM) to assess tumor size in cases of AD, as physical examination alone is insufficient.
• Consider both core lesion and thin spicules in mammographic measurements to improve size estimation accuracy.
• Employ multiple imaging modalities, especially in high breast density cases, to improve lesion characterization.

Management

• Base preoperative chemotherapy and surgical planning on clinical tumor staging derived from imaging.
• Avoid underestimation of tumor size to reduce risk of incomplete surgical margins and re-excision.
• Avoid overestimation to prevent unnecessary aggressive treatments and less conservative surgeries.

Monitoring & Follow-up

• Use imaging follow-up to monitor tumor size changes, especially when neoadjuvant chemotherapy is not administered.
• Correlate imaging findings with pathological results post-surgery for accurate staging.

Risks

• Underestimating tumor size on imaging may lead to incomplete excision and need for reoperation.
• Overestimating tumor size may result in overtreatment and unnecessary extensive surgery.

Patient & Prescribing Data

Women aged 50-69 diagnosed with invasive carcinoma presenting as architectural distortion on breast imaging

Imaging-based clinical tumor staging is critical for guiding preoperative chemotherapy and surgical decisions; accurate tumor size measurement impacts treatment planning.

Clinical Best Practices

• Perform biannual digital mammography screening in asymptomatic women aged 50-69.
• Use DBT, MRI, and CEM selectively in patients with high breast density or inconclusive findings on DM and US.
• Measure tumor size on multiple imaging modalities, including both core lesion and thin spicules on mammography, to improve correlation with pathological size.
• Ensure radiologists interpreting images are blinded to pathological staging to reduce bias in size measurement.
• Integrate imaging findings with histological subtype to refine tumor size assessment and staging.

References

• American College of Radiology BI-RADS Atlas
• Breast Imaging Reporting and Data System (BI-RADS) 5th Edition
• TNM Classification of Malignant Tumors, 8th Edition